
A Deluge of New Drugs for COVID
Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments—and fresh uses for familiar therapies.
Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments—and fresh uses for familiar therapies.
Researchers are trying to establish whether existing COVID-19 vaccines and treatments can prevent lasting symptoms
A rapidly spreading variant could dangerously strain health-care systems, even if the severe disease risk is relatively low for an individual
With vaccination campaigns underway in some countries while others weigh the options, Nature looks at the evidence for vaccinating younger people
At a pivotal moment in the pandemic, Nature explores key questions about the vaccines that countries are racing to deliver while viral variants spread around the globe
People older than 80 who waited 11 to 12 weeks for their second jab had higher peak antibody levels than did those who waited only three weeks
Preliminary results suggest the vaccine is up to 77 percent effective in young children, but researchers await larger studies
Researchers are searching for possible links between unusual clotting and the Oxford-AstraZeneca coronavirus vaccine
Organoids made of tear-producing cells offer chances to study, and possibly treat, eye disorders
Uptake by patients and physicians has been low in the U.S. even though some therapies have been authorized for months
Two RNA vaccines will be useful as U.S. infections surge, but the speedy authorizations complicate clinical trials
Despite conflicting data, the highly anticipated results will make the treatment a standard of care in the U.S.
Despite calls for more rigorous clinical trials, the Food and Drug Administration has granted an emergency authorization for the therapy
Remote clinical trials and other changes could permanently alter pharmaceutical development
Three studies showing large DNA deletions and reshuffling heighten safety concerns about heritable genome editing
With politicians touting the potential benefits of malaria drugs to fight COVID-19, some people are turning away from clinical trials of other therapies
As the first clinical trial results trickle in, researchers look ahead to more sophisticated medical applications for genome editing
The experiment tests a gene-editing therapy for a hereditary blindness disorder
As lung injuries among e-cigarette users mount amid a youth vaping epidemic, the impact of new restrictions remains unclear
The startling discovery could open up avenues for treating some aggressive tumors
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account